期刊文献+

叶氏狼疮方诱导狼疮肾炎患者T细胞免疫耐受分子机制研究

Molecular Mechanism of Ye's Lupus Formula on Induction of Peripheral Blood T Lymphocytes Tolerance in the Patients with Lupus Nephritis
下载PDF
导出
摘要 目的:探讨叶氏狼疮方在诱导狼疮肾炎(lupus nephritis,LN)患者外周血T淋巴细胞免疫耐受中有无作用。方法:密度梯度离心法提取LN患者及健康对照外周血单个核细胞(PBMCs),设立4个培养亚组:空白(blank)、植物血凝素(PHA)、狼疮方血清(lupus formula serum,LFS)、PHA+LFS组。双色标记流式细胞术检测PBMCs及其条件培养后CD3+T细胞表面分子CD28,CD40L,LFA-1a和CTLA-4的表达水平。多组间比较采用单因素方差分析。结果:活动性LN组外周血T细胞表面CD28、CD40L、LFA-1a和CTLA-4表达水平较健康对照组明显上调(P均<0.01);PHA可诱导健康对照T细胞表面CD28和CD40L表达明显上调(P均<0.01),但对其CTLA-4和LFA-1a的表达无明显影响(P均>0.05);而PHA对活动性LN组外周血T细胞表面上述指标表达均有明显上调作用(P均<0.05);叶氏狼疮方对健康人外周血T细胞表面上述指标的表达无明显影响,但可逆转活动性LN患者外周血T细胞表面的CD40L、LFA-1a过度表达(P均<0.05),对其CD28和CTLA-4过度表达无明显影响(P均>0.05);且叶氏狼疮方对PHA所诱导的活动性LN患者外周血T细胞表面CD28、CD40L和LFA-1a表达增加亦有明显抑制。结论:叶氏狼疮方可能主要通过下调T细胞CD40L和LFA-1a表达水平来诱导LN患者外周T细胞免疫耐受重建。 Objective:To investigate the effect of Ye's Lupus Formula on expression mode of costimulatory molecules group of T lymphocytes in the patients with lupus nephritis (LN).Methods:The peripheral blood mononuclear cells of female LN patients and healthy females were abstracted by density gradient centrifugation.The Levels of CD28,CD40L,CTLA-4 and LFA-1a expression on the peripheral blood T lymphocytes were detected by double-colored flow cytometry.The difference of their means were tested by analysis of variance (ANOVA).Results:Compared with the healthy controls,there were significantly higher level of CD28,CD40L,LFA-1a and CTLA-4 expression on the peripheral blood T cells in active LN patients(P〈0.01).To the healthy controls,higher levels of CD28 and CD40L expression on the peripheral blood T cells could be induced by PHA(P〈0.01),but not CTLA-4 and LFA-1a expression (P〈0.05).To the LN patients,higher levels of all the above molecules expressions on the peripheral blood T cells could be induced by PHA(P〈0.05).LFS could significantly inhibit over expression of LFA-1a and CD40L but for CD28 and CTLA-4 on the T cells of active LN patients(P〈0.05),but did not affect the levels of all the above molecules expressions on the T cells of healthy controls.Further more,LFS could markedly inhibit all the above molecules' over expression induced by PHA on the T cells of active LN patients.Conclusion:Ye's Lupus Formula may be helpful to reestablish the immune tolerance of the peripheral blood T cells by down-regulation of CD40L and LFA-1a expression level on the peripheral blood T cells in LN patients.
出处 《中国中西医结合肾病杂志》 2009年第12期1059-1062,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 广东省中医药管理局基金资助项目(No.1050034)
关键词 狼疮肾炎 T细胞免疫耐受 叶氏狼疮方 Lupus nephritis T lymphocytes immune tolerance Ye's lupus formula
  • 相关文献

参考文献9

  • 1Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med,2008,358(9) :929 - 939.
  • 2Dolff S, Wilde B, Patschan S, et al. Peripheral circulating activated b- cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus. Scand J Immunol,2007,66(5) :584 - 590.
  • 3Mount GR,Gilliland WR. Emerging biological therapies in systmaic lupus erythmaatosus. Clin pharmacol ther,2008,83( 1 ) : 167 - 171.
  • 4董光富,叶任高,张晓,石韫珍,崔阳,罗日强.不同免疫抑制方案对狼疮肾炎患者预后的影响[J].中华风湿病学杂志,2004,8(10):604-607. 被引量:7
  • 5Barreto M, Santos E, Ferreira R, et al. Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus. Eur J Hum Genet, 2004,12(8) :620 - 626.
  • 6董光富,张晓,林秋雄,张光锋,刘冠贤.来氟米特抑制狼疮肾炎患者树突状细胞成熟的实验研究[J].中国中西医结合肾病杂志,2008,9(4):309-312. 被引量:6
  • 7Crow MK. Costimulatory molecules and T - cell - B - cell interactions. Rheum Dis Clin North Am, 2004,30( 1 ) : 175 - 191.
  • 8Oosterwegel MA, Greenwald R J, Mandelbrot DA, et al. CTLA -4 and T cell activation. Curr Opin Immunol, 1999, 11 (3): 294 - 300.
  • 9Liu MF, Wang CR, Chen PC, et al. Increased expression of soluble cytotoxic T - lymphocyte - associated antigen - 4 molecule in patients with systemic lupus erythematosus. Scand J Immunol, 2003,57(6) :568 - 572.

二级参考文献24

  • 1Bombardier C, Gladman DD, Urowiz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum, 1992, 35: 630-640.
  • 2Kuiper-Geertsma DG, Derksen RH. Newer drugs for the treatment of lupus nephritis. Drugs, 2003, 63: 167-180.
  • 3Mok CC, Lai KN. Myeophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis, 2002, 40:447-457.
  • 4Zandman-Goddard G, Shoenfeld Y. Novel approaches to therapy for SLE. Clin Rev Allergy Immunol, 2003, 25:105-112.
  • 5Foster MH. T cells and B cells in lupus nephritis. Semin Nephrol,2007,27( 1 ) :47 - 58.
  • 6Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum,2006,36(2) :71 - 81.
  • 7Tam LS,Li EK,Wong CK,et al. Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis,2006,65(3) :417 - 418.
  • 8Tam LS, Li EK,Wong CK, et al. Double- blind, randomized, placebo- controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus, 2004,13 (8) : 601 - 604.
  • 9Morris RE, Huang X,Cao W,et al. Leflunomide (HWA 486) and its analog suppress T - and B - cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc, 1995,27( 1 ) :445 - 447.
  • 10Kessel A, Toubi E. Leflunomide in systemic lupus erythematosus. Harefuah,2002,141 (4) :355 - 357,409.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部